Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial

Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial Publisher

Sadeghi A¹ ; Saedisomeolia A^{1, 2} ; Jalilibaleh L³ ; Khoobi M⁴ ; Soleimani M⁵ ; Fakhr Yasseri AM⁶ ; Yekaninejad MS⁷ ; Farzin A⁸ ; Amini E⁸ ; Nowroozi MR⁸

Show Affiliations

1. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran
2. School of Human Nutrition, McGill University, Montreal, QC, Canada
3. Department of Medical Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Urology, Modares University Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6. Endologist, Shariati Hospital, Alborz University of Medical Sciences, Karaj, Iran
7. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
8. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Nutrition Published:2022

Abstract

Background: For decades, lycopene was considered the main compound of tomato protecting benign prostatic hyperplasia (BPH). Recent animal studies suggest that a newly discovered compound “FruHis” boosts lycopene for its action. This study aimed to determine whether FruHis enhances the action of lycopene to modify the laboratory parameters and clinical outcomes of patients with BPH. Materials and methods: Current study was conducted on 52 BPH patients, who were randomly assigned into four groups of treatments: lycopene plus FruHis (n = 11, 25 mg/day lycopene and 10 mg/day FruHis), lycopene (n = 12, 25 mg/day lycopene), FruHis (n = 12, 10 mg/day FruHis), and placebo (n = 13). Patients received these supplements for 8 weeks. Results: FruHis intake strengthened the reducing effects of lycopene on insulin-like growth factor-1 (IGF-1) (−54.47 ± 28.36 ng/mL in the lycopene + FruHis group vs. −30.24 ± 46.69 ng/mL in the lycopene group), total prostate-specific antigen (TPSA) (−1.49 ± 4.78 ng/mL in the lycopene + FruHis group vs. −0.64 ± 2.02 ng/mL in the lycopene group), and symptom score (−4.45 ± 4.03 in the lycopene + FruHis group vs. −1.66 ± 5.41 in the lycopene group) in BPH patients. Such findings were also seen for body mass index (BMI) and waist circumference (WC). However, except for IGF-1, these reductions were not statistically significant compared with the placebo, and the intakes of lycopene and FruHis alone, however, were clinically important. Such effects of lycopene and FruHis were not seen for free PSA (FPSA) and FPSA/TPSA ratio. Conclusion: Despite the non-significant effects of lycopene and FruHis, it seems that FruHis intake strengthens the beneficial effects of lycopene on IGF-1, TPSA, and symptom scores among BPH patients. Clinical trial registration: [www.irct.ir], identifier [IRCT20190522043669N1]. Copyright © 2022 Sadeghi, Saedisomeolia, Jalili-Baleh, Khoobi, Soleimani, Fakhr Yasseri, Yekaninejad, Farzin, Amini and Nowroozi.

Style	Citing Format
MLA	Sadeghi A, et al.. "Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial." Frontiers in Nutrition, vol. 9, no. , 2022, pp. -.
APA	Sadeghi A, Saedisomeolia A, Jalilibaleh L, Khoobi M, Soleimani M, Fakhr Yasseri AM, Yekaninejad MS, Farzin A, Amini E, Nowroozi MR (2022). Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial. Frontiers in Nutrition, 9(), -.
Chicago	Sadeghi A, Saedisomeolia A, Jalilibaleh L, Khoobi M, Soleimani M, Fakhr Yasseri AM, Yekaninejad MS, Farzin A, Amini E, Nowroozi MR. "Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial." Frontiers in Nutrition 9, no. (2022): -.
Harvard	Sadeghi A et al. (2022) 'Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial', Frontiers in Nutrition, 9(), pp. -.
Vancouver	Sadeghi A, Saedisomeolia A, Jalilibaleh L, Khoobi M, Soleimani M, Fakhr Yasseri AM, et al.. Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial. Frontiers in Nutrition. 2022;9():-.
BibTex	@article{ author = {Sadeghi A and Saedisomeolia A and Jalilibaleh L and Khoobi M and Soleimani M and Fakhr Yasseri AM and Yekaninejad MS and Farzin A and Amini E and Nowroozi MR}, title = {Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial}, journal = {Frontiers in Nutrition}, volume = {9}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Sadeghi A AU - Saedisomeolia A AU - Jalilibaleh L AU - Khoobi M AU - Soleimani M AU - Fakhr Yasseri AM AU - Yekaninejad MS AU - Farzin A AU - Amini E AU - Nowroozi MR TI - Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial JO - Frontiers in Nutrition VL - 9 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract